Advances of immunotherapy in refractory thyroid carcinoma
10.3760/cma.j.issn.1674-6090.2020.01.018
- VernacularTitle:难治性甲状腺癌免疫治疗的研究进展
- Author:
Jianlu SONG
1
;
Ting YAN
;
Zhili YANG
Author Information
1. 上海交通大学附属第六人民医院甲乳疝外科 200233
- From:Chinese Journal of Endocrine Surgery
2020;14(1):80-82
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, the incidence of thyroid cancer has increased significantly and it has become the most common malignant tumor of the endocrine system. Despite the favorable prognosis of most thyroid cancers, a small fraction of differentiated thyroid carcinomas and almost all anaplastic thyroid carcinomas grouped together as "refractory thyroid carcinoma (RTC) " , remain resistant to standard treatment options, including early surgery and radioactive 131I treatment. It is unclear what treatment is best for cases of RTC. Tumor immunotherapy is an emerging treatment after surgery, radiotherapy, chemotherapy and targeted therapy. Immunotherapy has shown great potential in various malignant tumors and may provide a new choice for the treatment of RTC.
